Post-Prostatectomy Recurrence
After the prostate is surgically removed, PSA should become undetectable, because the gland that produced it is gone. A PSA level that becomes detectable again and rises on repeat testing indicates that prostate cancer cells have survived somewhere—this is biochemical recurrence, and it is the earliest sign that treatment has not eliminated the disease. It affects a meaningful minority of men after surgery, often years later. Importantly, a rising PSA is not the same as advanced cancer: many men have small amounts of disease confined to the surgical bed that further treatment can still cure, and the entire purpose of the evaluation that follows is to work out where the cancer is and whether it remains curable.
What is it?
Prostate-specific antigen is produced by prostate tissue. When the entire prostate is removed in a radical prostatectomy, the source of PSA is removed with it, and the level in the blood should fall to undetectable within roughly six weeks—the time required for existing circulating PSA to clear.
A PSA that becomes detectable again, and rises on subsequent testing, means prostate cells producing PSA remain somewhere in the body. Because the only prostate cells that should exist after surgery are cancer cells that escaped removal, a rising PSA is taken as evidence of recurrent cancer.
This is termed biochemical recurrence, and the conventional definition is a PSA of 0.2 nanograms per millilitre or higher, confirmed on a second sample. Some centres use ultrasensitive assays capable of detecting far lower levels, which identify recurrence earlier but also generate uncertainty, since very low detectable levels do not always progress.
One important nuance: a small amount of benign prostate tissue is occasionally left behind at the margins of surgery, and this can produce a low, stable, detectable PSA that never rises. What distinguishes recurrence is not a single detectable value but a rising trend on repeated testing, which is why the pattern over time matters more than any individual result.
The critical question once recurrence is established is where the cancer is, because this determines whether it is still curable.
Local recurrence means cancer remaining in the prostate bed—the space where the prostate used to sit—usually from microscopic disease at the surgical margin. This is potentially curable with radiotherapy to that area.
Regional recurrence means disease in the pelvic lymph nodes. This may still be treatable with curative intent in selected men, typically with radiotherapy covering the nodes alongside hormonal therapy.
Distant recurrence means disease in bone or elsewhere. Cure is generally not achievable, though long-term control frequently is, and an emerging exception exists for men with only a small number of deposits.
Several features help predict which of these is most likely, and they are used together rather than individually.
The time from surgery to recurrence is informative: recurrence within the first one to two years is more often associated with distant disease, while later recurrence more often reflects local disease.
PSA doubling time—how quickly the level is rising—carries substantial weight. A short doubling time, particularly under six months, suggests more aggressive disease and a higher likelihood of distant spread, while a long doubling time suggests indolent, more likely local disease.
The pathology from the original surgery contributes: Grade Group, whether cancer extended beyond the prostate capsule, whether the seminal vesicles were involved, whether surgical margins were positive, and whether lymph nodes contained cancer. Positive margins in particular favour local recurrence, since they indicate cancer was cut across at the edge of the specimen.
The absolute PSA level at the time of recurrence matters for imaging, since detection rates rise with higher PSA.
Symptoms are characteristically absent. Biochemical recurrence is by definition a laboratory finding that precedes any physical manifestation, and most men feel entirely well. This can be disorienting: a man who feels healthy is told his cancer has returned on the basis of a number. Understanding that this is the intended purpose of monitoring—finding disease while it is still small and treatable—helps make sense of it.
Symptoms, when they occur, generally indicate more established disease: persistent bone pain, urinary difficulty or bleeding, pelvic discomfort, leg swelling, weight loss, or fatigue. New leg weakness, numbness, or loss of bladder or bowel control may indicate spinal cord compression and constitutes an emergency.
The evaluation of a rising PSA has changed more in the past decade than almost any other area of prostate cancer care, and the change is attributable to one development.
PSMA PET-CT targets prostate-specific membrane antigen, a protein expressed on the surface of prostate cancer cells, allowing the cancer itself to be visualised rather than its secondary effects. Its impact in this setting is substantial, because conventional imaging—CT and bone scan—detects almost nothing at the low PSA levels at which recurrence is typically identified. A man with a PSA of 0.3 would historically have had normal scans and been treated empirically on the assumption that disease was local. PSMA PET-CT detects disease in a meaningful proportion of such men, and detection rates climb steadily as PSA rises. Studies have consistently shown that it changes the intended management in a substantial share of cases—identifying nodal or distant disease that redirects treatment, or confirming disease confined to the prostate bed that supports proceeding with salvage radiotherapy.
Multiparametric MRI of the pelvis assesses the prostate bed directly and can identify local recurrence as a nodule at the site of the surgical anastomosis, and it also evaluates pelvic nodes. It is useful alongside PSMA imaging and in centres where PSMA is unavailable.
Conventional CT and bone scintigraphy have limited yield at low PSA levels and are largely reserved for higher PSA values or where PSMA PET is not accessible.
Biopsy of the prostate bed is occasionally performed but is not routinely required, since a rising PSA after prostatectomy is itself considered sufficient evidence of recurrence, and negative biopsies are common even when local recurrence is present.
An important practical tension deserves acknowledgement. The evidence supporting salvage radiotherapy shows it works best when given early, at the lowest possible PSA. But imaging is least informative at low PSA. This creates a genuine dilemma: waiting for PSA to rise enough for imaging to localise the disease may mean losing the window in which treatment is most effective. Different teams weigh this differently, and it is a reasonable question for a man to ask directly—whether to proceed with treatment now on probability, or to image first and accept some delay.
Important to Know
The most important framing for a man told his PSA is rising after surgery is that this is not the same as being told the cancer has spread. Many men in this situation have small-volume disease confined to the prostate bed that further treatment can cure, and even where cure is not achievable, prostate cancer is frequently controlled for many years. Care is coordinated by urology and radiation oncology, with medical oncology involvement as needed.
Confirming the finding comes first. A single detectable PSA is repeated before acting on it, since laboratory variation occurs and a stable low level can reflect residual benign tissue rather than cancer. The trend over several measurements is what matters.
Salvage radiotherapy to the prostate bed is the standard treatment when recurrence is likely local. The evidence on timing is consistent and important: outcomes are substantially better when radiotherapy is given at a low PSA, generally below 0.5 and ideally lower still, than when it is delayed until the level has climbed. This is the main argument against a prolonged period of watching, and it is worth understanding because deferral can feel like the cautious option when it may not be.
Adding hormonal therapy to salvage radiotherapy improves outcomes in men with higher-risk features, and radiotherapy fields are extended to cover the pelvic lymph nodes in selected men. These decisions are individualised using the PSA level, doubling time, original pathology, and imaging findings, and validated prediction tools are often used to estimate benefit.
An important shift in practice concerns early salvage versus adjuvant treatment. Radiotherapy was previously given routinely after surgery to men with adverse pathology, before any PSA rise. Trial evidence has since shown that giving radiotherapy only when PSA begins to rise—early salvage—produces comparable outcomes while sparing radiotherapy entirely in the substantial proportion of men who never recur. Early salvage is now the preferred approach in most situations, which is precisely why careful PSA monitoring after surgery matters so much.
Where imaging identifies disease in pelvic lymph nodes, treatment can be extended to include those nodes with curative intent in appropriately selected men.
Oligometastatic recurrence—a small number of distant deposits, typically fewer than three to five—is an area of genuine and rapid change. Targeted radiotherapy delivered to each visible deposit, often alongside systemic treatment, is increasingly used and has shown promise in delaying progression and the need for hormonal therapy. The evidence base is still maturing, and the increased detection of small-volume disease by PSMA imaging has expanded this category considerably. Men in this situation should ask about clinical trials, which are actively recruiting in this space.
For more widespread recurrence, systemic treatment follows the principles used in metastatic disease, with combination therapy from the outset now standard rather than hormonal treatment alone.
Observation is a legitimate option in selected circumstances. A man with a long PSA doubling time, favourable original pathology, advanced age, or significant other health problems may reasonably be monitored, since the cancer may never cause him harm and treatment carries side effects. This is a considered strategy rather than neglect, and it is chosen on the basis of the specific numbers rather than as a default.
Side effects of salvage radiotherapy are worth knowing before deciding. Urinary irritative symptoms and worsening of any existing incontinence, bowel effects including urgency and bleeding, and further impairment of erectile function are the main considerations, and they compound effects already present from surgery. Modern techniques including image guidance and, in some centres, rectal spacers reduce these. Hormonal therapy adds hot flushes, fatigue, muscle loss, weight gain, bone density loss, and mood effects.
Genetic testing is increasingly recommended, particularly where disease is aggressive or recurrence is early, since BRCA2 and other DNA repair alterations affect treatment options and carry implications for relatives.
Monitoring after salvage treatment continues with PSA, and the pattern of response indicates whether treatment has worked. An undetectable PSA after salvage radiotherapy is a favourable sign.
The psychological impact deserves acknowledgement rather than being treated as secondary. Men who believed their cancer was cured and who feel entirely well can find a rising number profoundly destabilising, and anxiety around each subsequent PSA test is common and normal. Support is available and worth accessing.
Care is coordinated by urology and radiation oncology, and a second opinion is reasonable given that treatment approaches differ meaningfully and the decision has long-term consequences. PSA kinetics, imaging, original pathology, and clinical findings are interpreted together alongside age, health, and personal priorities.
Patient education plays an important role. Understanding that a rising PSA is not equivalent to metastatic disease, that the trend matters more than a single value, that salvage radiotherapy works best early, why imaging may not show anything at low PSA levels, and which symptoms require urgent attention all contribute to appropriate care and informed decision-making.
Red flag symptoms include new or worsening back pain, particularly when worse lying flat or with coughing; any new leg weakness, numbness, tingling, or difficulty walking; loss of bladder or bowel control, or new inability to pass urine; persistent bone pain in the hips, pelvis, or ribs; blood in the urine; new leg swelling; unexplained weight loss; and a rapidly rising PSA over a short interval. New neurological symptoms require immediate emergency assessment, as spinal cord compression is time-critical and function lost before treatment often does not return.